MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1684/ejd.2014.2368

Медицинская библиотека · European journal of dermatology : EJD · 2014

The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).

Tzogani Kyriaki, Nagercoil Nithyanandan, Hemmings Robert James, Samir Bekkai, Gardette Jean, Demolis Pierre, Salmonson Tomas, Pignatti Francesco

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

The European Commission has recently issued a marketing authorisation valid throughout the European Union for ingenol mebutate (Picato) in the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults.

OBJECTIVES

The objective of this paper is to summarise the scientific review of the application leading to regulatory approval in the EU. The full scientific assessment report and product information, including the summary of product characteristics, are available on the EMA website (www.ema.europa.eu).

MATERIAL &

METHODS

The application was supported by 25 clinical studies, of which 18 were performed in patients with actinic keratosis.

RESULTS

The active substance is a pure ingenol angelate obtained from the aerial parts of the plant species Euphorbia peplus by extraction and purification. One tube of ingenol mebutate 150 mcg/g gel or 500 mcg/g gel should be applied once daily to the affected area for 3 or 2 consecutive days on the 'face and scalp' or 'trunk and extremities', respectively. Complete response rate is 42.2% on the 'face and scalp' and 34.1% on the 'trunk and extremities'. The most common side effects are local skin responses including erythema, flaking/scaling, crusting, swelling, vesiculation/pustulation and erosion/ulceration at the application site.

CONCLUSIONS

The benefits of ingenol mebutate are its ability to improve the complete response rate of actinic keratosis, the short duration of treatment and the ease of self-application.

Для цитирования: Tzogani Kyriaki, Nagercoil Nithyanandan, Hemmings Robert James, Samir Bekkai, Gardette Jean, Demolis Pierre, Salmonson Tomas, Pignatti Francesco. The European Medicines Agency approval of ingenol mebutate (Picato) for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults: summary of the scientific assessment of the Committee for Medicinal Products for Human Use (CHMP).. European journal of dermatology : EJD. 2014. DOI: 10.1684/ejd.2014.2368.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.